menu
    • menu
    [{"orgOrder":0,"company":"Advanced Bioscience laboratories","sponsor":"DAIDS","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"HIV-1 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Advanced Bioscience laboratories","amount2":0.35999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"Advanced Bioscience laboratories \/ DAIDS","highestDevelopmentStatusID":"4","companyTruncated":"Advanced Bioscience laboratories \/ DAIDS"},{"orgOrder":0,"company":"Advanced Bioscience laboratories","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"MVA-based SARS-CoV-2 Vaccine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Bioscience laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Advanced Bioscience laboratories \/ Advanced Bioscience Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Bioscience laboratories \/ Advanced Bioscience Laboratories"}]

    Find Clinical Drug Pipeline Developments & Deals by Advanced Bioscience laboratories

    Menu

    Advanced Bioscience laboratories

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Advanced Bioscience laboratories

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Advanced Bioscience laboratories

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MVA-based SARS-CoV-2 Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : GeoVax Labs

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates

                            Details : The partnership will support current Good Manufacturing Practices production of the company’s vaccine candidates, including GEO-MVA and GEO-CM04S1 (MVA-based SARS-CoV-2 vaccine), a next-generation COVID-19 vaccine based on GeoVax’s MVA viral vector p...

                            Brand Name : GEO-CM04S1

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 31, 2023

                            Lead Product(s) : MVA-based SARS-CoV-2 Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : GeoVax Labs

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Advanced Bioscience laboratories

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Advanced Bioscience laboratories

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HIV-1 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : DAIDS

                            Deal Size : $364.5 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ABL Awarded NIH Contract for Continued Support of HIV Vaccine Development

                            Details : ABL will provide DAIDS with preclinical and translational development of promising vaccines and related products for HIV and other candidate agents.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 20, 2022

                            Lead Product(s) : HIV-1 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : DAIDS

                            Deal Size : $364.5 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth